Repligen (NASDAQ:RGEN) Issues FY 2026 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 2.030-2.090 for the period, compared to the consensus EPS estimate of 2.000. The company issued revenue guidance of $813.0 million-$835.0 million, compared to the consensus revenue estimate of $819.5 million.

Repligen Price Performance

RGEN traded up $19.61 on Tuesday, hitting $150.67. 271,811 shares of the stock were exchanged, compared to its average volume of 1,002,488. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. Repligen has a 12 month low of $100.99 and a 12 month high of $175.77. The firm has a market capitalization of $8.50 billion, a price-to-earnings ratio of 169.93, a PEG ratio of 2.54 and a beta of 1.06. The business has a 50-day moving average of $132.21 and a two-hundred day moving average of $132.05.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same period in the prior year, the business posted $0.26 earnings per share. The firm’s revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts forecast that Repligen will post 1.99 EPS for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of several research analyst reports. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. HSBC decreased their price target on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Canaccord Genuity Group dropped their target price on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Wolfe Research began coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective on the stock. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $165.36.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.60% of the company’s stock.

Key Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen delivered Q2 revenue of $204.1 million, up 11.9% year over year and above the $201.6 million consensus estimate. Organic revenue growth was 13%, reflecting continued order momentum and sequential improvement. Repligen Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Adjusted diluted EPS was $0.54, exceeding the $0.45 analyst consensus and rising from $0.37 a year earlier. Adjusted operating income increased 55% to $34 million, while adjusted operating margin expanded to 16.7% from 12.0%. Repligen Quarterly Earnings Results
• Positive Sentiment: Management raised full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09, above the approximately $2.00 consensus EPS forecast. Total reported revenue is expected to reach $813 million-$835 million. Repligen Raises Full-Year Guidance
• Positive Sentiment: Repligen announced a definitive agreement to acquire BioLife Solutions, a deal management expects to strengthen its cell-therapy position and contribute to revenue growth, margins and adjusted EPS. The company ended June with $810 million in cash, cash equivalents and marketable securities, supporting financial flexibility.
• Neutral Sentiment: Investors must distinguish the adjusted results from GAAP results: GAAP diluted EPS fell to $0.09 from $0.26, while net income declined to $5.0 million from $14.9 million. The difference was driven largely by acquisition, restructuring, transformation, amortization and other items.
• Negative Sentiment: GAAP net margin dropped to 2.5% from 8.2%, and GAAP operating margin edged down to 6.8% from 7.6%. These figures may temper enthusiasm, particularly given RGEN’s elevated valuation, including a reported price-to-earnings ratio above 145.
• Negative Sentiment: The BioLife Solutions transaction remains subject to completion and integration risks, while recent insider activity cited in the coverage showed two sales and no purchases over the past six months.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in RGEN. United Capital Financial Advisors LLC bought a new position in Repligen in the third quarter valued at about $368,387,000. Opti Capital Management LP bought a new stake in Repligen during the fourth quarter valued at approximately $2,399,209,000. Price T Rowe Associates Inc. MD grew its position in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares during the period. RTW Investments LP purchased a new stake in Repligen during the fourth quarter valued at approximately $174,347,000. Finally, Balyasny Asset Management L.P. raised its position in Repligen by 390.6% in the third quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock worth $102,557,000 after acquiring an additional 610,837 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.